Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx) -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (313)	10/1/2007 4:36:44 PM
From: Keith Feral	Respond to of 418

Cofactor and Avastin for one.

To: DewDiligence_on_SI who wrote (313)	10/1/2007 5:10:42 PM
From: Keith Feral	Read Replies (1) \| Respond to of 418

I went back and looked at all the bolus and infusional regimens. All the people that are studying other drugs like FOLFOX and FOLFIRI are using infusional 5FU and leucovorin. It is considered safer and more efficacious than bolus 5FU and leucovorin. That's not really the point of Cofactor's trial, which is to determine whether bolus Cofactor or infusional Cofactor works better than bolus Leucovorin or infustional Leucovorin. Bolus Cofactor has demonstrated statistically significant benefits over Bolus Leucovorin, and Infusional Cofactor has not demonstrated statistically significant improvements. The trending results for efficacy were better in each regard, except for response rates. The trending improvements for Cofactor toxicity profile was better across the board. However, bolus 5FU and Cofactor had better results than infusional 5FU and Cofactor and better results than infusional 5FU and Leucovorin. I guess the debate would hinge on the Roswell Park daily regimen vs the de Gramont be weekly regimen. It's not clear to me which would be better for leucovorin based on the new results from the Cofator and Leucovorin trial with infusional 5FU. However, the results for bolus Cofactor are much better than infusional Cofactor. Anyways, there can't be any clear answer to which type of regimen is better because many treatments use Xeloda, which does not have any Leucovorin. I have no question in my mind that some form of intravenous folate, either leucovorin or cofactor, would be better than none. Still, many oncologists use the drug because they think it gets the job done.

To: DewDiligence_on_SI who wrote (313)	10/4/2007 6:58:20 PM
From: Keith Feral	Read Replies (1) \| Respond to of 418

I went through all the infusional therapies one more time. When I made the comment about infusional therapy, I was focusing on DeGramont regimen which preloads 5FU and LV infusionally for 2 hours and then infuses 5FU for 22 hours via pump. There are only a few centers out there that still use 5FU/LV infusional DeGramont as the standard of care. Most places now use much better forms of combination therapy which all use different types of bolus or infusional administration of 5FU/LV or ILF plus some other drug like Avastin.